fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Pizotyline

All products: general benefit

Sandomigran DS · DIN 00511552 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Sandomigran DS · DIN 00511552 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Marketed since 2025-11-28 · brand SANDOMIGRAN DS · ATC N02CX01 PIZOTIFEN · form Tablet · route Oral · ingredients PIZOTIFEN (PIZOTIFEN MALATE) 1 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandomigran DS: Formulary list price $1.19 per unit (the source does not state the unit; exact figure $1.1932). What the ministry pays, not the patient.

Ministry pays: $1.1932 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00511552)

Source record
DIN 00511552: Sandomigran DS Raw flags: sec3=Y Item: 289200031; group id 542; item number 1461; lccId None; manufacturer id KNT Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $1.1932; ministry $1.1932 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00511552 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4222
Shortage status: active shortage (reported October 2, 2023, estimated to end December 12, 2026, last updated September 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00511552
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N02C): coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Eletriptan (Relpax): not a benefit
  • Frovatriptan (Frova): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Sumatriptan (Imitrex): not a benefit

1 more in the class list below

Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 38 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS SANDOMIGRAN DS (pizotifen tablets) is indicated for: • the prophylactic management of migraine. In various clinical trials, about 1/3 to 2/3 of patients with migraine experienced some benefit from SANDOMIGRAN DS and in most trials it was more effective than placebo in reducing the frequency or severity of attacks. SANDOMIGRAN DS is not useful for the clinical treatment of acute migrainous attack or for the treatment of tension headaches. 1.1 Pediatrics Pediatrics (< 12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of SANDOMIGRAN DS in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 2 CONTRAINDICATIONS). Adolescents (12-17 years of age): There is limited evidence supporting the safety and efficacy of SANDOMIGRAN DS in adolescents 12-17 years of age, therefore SANDOMIGRAN DS should be used with caution in this age group (see 4.2 Recommended Dose and Dosage Adjustment). 1.2 Geriatrics Geriatrics (>65 years of age): The safety and efficacy of SANDOMIGRAN DS in patients 65 years of age or older have not been established. Caution… https://pdf.hres.ca/dpd_pm/00082624.PDF PM date: NOV 28, 2025 Source product: SANDOMIGRAN DS; DIN 00511552; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sandomigran DS · DIN 00511552 Shortage status: active shortage (reported 2023-10-02, estimated to end 2026-12-12, last updated 2026-09-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00511552

Check this DIN again